[DISCLOSURE] Samsung BioLogics (207940) announced on July 21 that it has signed a 15.73 billion won (US$14.06 million) contract manufacturing deal with a European pharmaceutical company. 

This amounts to 5.34 percent of its 2016 revenue and the exclusive contract period will remain undisclosed until Dec. 31, 2019 to protect trade secrets. 

By Hwang You-mee (theinvestor@heraldcorp.com)